SAUL EWING ARNSTEIN & LEHR: Lizza's Helsinn case heads to U.S. Supreme Court

By Press release submission | Jul 7, 2018

Saul Ewing Arnstein & Lehr issued the following announcement on June 28.

Saul Ewing Arnstein & Lehr Partner Charles M. Lizza, Chair of the Firm’s Intellectual Property Litigation practice, is a member of the legal team that just secured a grant of certiorari by the U.S. Supreme Court in the case of Helsinn Healthcare S.A., v. Teva Pharmaceuticals USA, Inc., et al. 

The Court agreed to review a Federal Circuit decision in a case of first impression that interpreted the on-sale bar provision in the America Invents Act to invalidate a Helsinn patent. 

Helsinn’s patent covers its Aloxi® brand drug product which treats chemotherapy-induced nausea and vomiting and has annual sales that exceeded a half billion dollars. In its petition for certiorari, Helsinn argued the ruling is "indefensible" and the result of a "profoundly flawed analysis." Legal experts have said the lower court’s ruling could put many patents at risk; therefore, the case will be closely watched by the pharmaceutical industry and the intellectual property bar.

Original source can be found here.

Want to get notified whenever we write about Saul Ewing Arnstein & Lehr ?

Sign-up Next time we write about Saul Ewing Arnstein & Lehr, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Saul Ewing Arnstein & Lehr

More News

The Record Network